Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fructin is a product developed by Nika BioTechnology (also known as Nika Pharmaceuticals), a Bulgarian company specializing in natural products, functional foods, and immunotherapies. Fructin is primarily marketed as a dietary supplement or functional food component, often associated with crystalline fructose or fruit-derived extracts. It is positioned within Nika's portfolio alongside other nutraceuticals and phytopreparations such as Carotilen, Anthocylen C, and Dry Boza, intended for metabolic support and as a healthier alternative to traditional sweeteners. While listed on the company's product pipeline, specific clinical trial data and pharmacological targets for Fructin are not extensively documented in standard pharmaceutical registries, reflecting its classification as a nutraceutical rather than a conventional pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fructin.